The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study.
Gut Liver
; 10(6): 910-916, 2016 Nov 15.
Article
em En
| MEDLINE
| ID: mdl-27282265
ABSTRACT
BACKGROUND/AIMS:
To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis.METHODS:
A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score.RESULTS:
The mean decreases in the total symptom score at 4 weeks were estimated to be -18.1±13.8 in the combination therapy group and -15.1±11.9 in the monotherapy group (p=0.011). Changes in reflux symptoms from baseline after 4 weeks of treatment were -8.4±6.6 in the combination therapy group and -6.8±5.9 in the monotherapy group (p=0.009).CONCLUSIONS:
Over a 4-week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esofagite Péptica
/
Quinolonas
/
Alanina
/
Inibidores da Bomba de Prótons
/
Esomeprazol
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article